Can you take Quadramet with Talazoparib?
1 drug interaction and 3 additional warnings found for the following 2 drugs:
- Quadramet (samarium sm 153 lexidronam)
- talazoparib
Drug interactions
Major drug interactions
Major:
samarium sm 153 lexidronam talazoparib
Applies to: Quadramet (samarium sm 153 lexidronam) and talazoparib
Using samarium sm 153 lexidronam together with talazoparib may increase the risk of side effects that affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
3 potential interactions Applies to: 3 conditions, including Liver Disease, Immunodeficiency, and Renal Dysfunction.
Immunodeficiency
Moderate:
talazoparib
Talazoparib has a moderate potential interaction with Immunodeficiency.
Myelosuppression consisting of anemia, leukopenia/neutropenia, and/or thrombocytopenia, have been reported in patients treated with talazoparib. Therapy with talazoparib should not be started in myelosuppressed patients and patients that have not adequately recovered from hematological toxicity caused by previous therapies. If myelosuppression occurs during therapy, dose modifications are recommended. Patients should be closely monitored.
Liver Disease
Moderate:
talazoparib
Talazoparib has a moderate potential interaction with Liver Disease.
Talazoparib has not been studied in patients with moderate hepatic impairment (total bilirubin >1.5 to 3.0 × upper limit of normal [ULN] and any aspartate aminotransferase [AST]) or severe hepatic impairment (total bilirubin >3.0 × ULN and any AST). No dose adjustment is required for patients with mild hepatic impairment (total bilirubin =1 × ULN and AST > ULN, or total bilirubin >1.0 to 1.5 × ULN and any AST).
Renal Dysfunction
Moderate:
talazoparib
Talazoparib has a moderate potential interaction with Renal Dysfunction.
Talazoparib has not been studied in patients with severe renal impairment (CrCl < 30 mL/min) or patients requiring hemodialysis. Caution is advised if used in these patients. A dose reduction is recommended in patients with moderate renal impairment (CrCl 30 - 59 mL/min), and no dose adjustment is required for patients with mild renal impairment (CrCl 60 - 89 mL/min).
Report options
More resources
Quadramet
A total of 223 drugs are known to interact with Quadramet.
- Quadramet is in the drug class therapeutic radiopharmaceuticals.
talazoparib
A total of 327 drugs are known to interact with talazoparib.
- Talazoparib is in the drug class PARP inhibitors.
- Talazoparib is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.